Amlodipine Does Not Reduce eGFR—It Actually Increases It
Amlodipine does not reduce eGFR; rather, it increases glomerular filtration rate and renal blood flow through renal arteriole vasodilation. This is a consistent finding across both FDA labeling and clinical guidelines.
Mechanism and Renal Effects
According to the FDA drug label, in hypertensive patients with normal renal function, therapeutic doses of amlodipine resulted in a decrease in renal vascular resistance and an increase in glomerular filtration rate and effective renal plasma flow without change in filtration fraction or proteinuria 1. This occurs because amlodipine, as a dihydropyridine calcium channel blocker, causes vasodilation of renal arterioles, which improves renal blood flow even while systemic blood pressure is reduced 2.
Clinical Evidence in CKD Patients
The 2018 British Journal of Pharmacology guideline specifically addresses this question: amlodipine has renoprotective effects in CKD patients, especially when paired with ARBs, and even a single dose of amlodipine can lead to a demonstrable increase in eGFR in CKD patients 2. The mechanism involves reduction in renal artery smooth muscle contraction leading to higher renal flow, even while systemic blood pressure is reduced.
Important Caveats and Context
Comparison with Other Agents
While amlodipine increases eGFR acutely, this differs from the expected initial eGFR decline seen with:
- ACE inhibitors and ARBs: These cause an expected eGFR dip of up to 30% through efferent arteriole vasodilation, which is actually associated with long-term kidney protection 3, 4
- SGLT2 inhibitors: These cause an initial small eGFR decrease (3-6%) that predicts better long-term outcomes 5, 6
Clinical Trial Data
In the IDNT trial comparing irbesartan, amlodipine, and placebo in diabetic nephropathy, amlodipine was associated with a faster rate of eGFR decline (-3.76 mL/min/1.73 m²/year) compared to irbesartan (-2.34 mL/min/1.73 m²/year) over the long term, despite the acute increase in eGFR 7. This suggests that the initial increase in eGFR with amlodipine may reflect increased intraglomerular pressure rather than true renal protection.
Intraglomerular Pressure Concerns
A critical distinction: amlodipine increases intraglomerular pressure by preferentially dilating afferent arterioles, whereas agents like manidipine do not increase intraglomerular pressure 8. This increased intraglomerular pressure may explain why amlodipine, despite increasing eGFR acutely, does not provide the same long-term renoprotection as RAAS inhibitors in proteinuric kidney disease.
Clinical Recommendations
For patients with CKD and proteinuria (UACR ≥30 mg/g), ACE inhibitors or ARBs should be first-line therapy, not amlodipine 9, 10, 3, 4. Amlodipine is appropriate as:
- Add-on therapy when blood pressure targets are not met with RAAS inhibitors and diuretics
- Alternative therapy in patients without albuminuria where ACE inhibitors/ARBs have not shown superior cardioprotection compared to calcium channel blockers 10
- Second-line option in ADPKD when diuretics are contraindicated 11
Monitoring
When using amlodipine, monitor eGFR at baseline and periodically, but do not expect an eGFR decline—if eGFR decreases significantly on amlodipine, investigate other causes such as volume depletion, AKI from other medications, or progression of underlying kidney disease 3, 4.
The 2013 ACC/AHA heart failure guideline notes that most calcium channel blockers (except amlodipine) should be avoided in heart failure as they are potentially harmful 12, though this relates to their negative inotropic effects rather than renal effects specifically.